| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 19.2 | 17.6 |
| Profit before tax | -8.3 | 8.9 |
| Net income | -5.8 | 5.8 |
| EPS (diluted, $ a share) | $-0.23 | $0.11 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +8.7% |
|---|---|
| Operating margin | -37.5% |
10-Q filed with the SEC, NASDAQ: FBIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Fortress Biotech, Inc.: key numbers
- Share price
- $1.71Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Fortress Biotech, Inc.
All →Fortress Biotech Financial Results
Fortress Biotech reported Q3 2026 financial results with total net revenue increasing 9% year-over-year to $19.2 million. During the quarter, the company repaid its Oaktree credit facility in full, leaving it with no outstanding debt at the parent level, and in-licensed FB-607 for the treatment of IBS-D.
- Term
- Q3 2026
“The third quarter of 2026 reflected continued execution across our diversified portfolio. In September, we repaid in full our credit facility with Oaktree and we also recently announced the in-licensing of FB-607, a novel combination therapy to treat the symptoms of irritable bowel syndrome with diarrhea (“IBS-D”).”
Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer
“With our growing royalty income from ZYCUBO® and UNLOXCYT™, and multiple potential catalysts across our partnered programs, we believe Fortress is well positioned to continue driving long-term value for our shareholders.”
Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer
Fortress Biotech Deal Termination with Oaktree Fund Administration, LLC
Fortress Biotech repaid in full its remaining $15.0 million outstanding principal under its senior secured credit agreement with Oaktree Fund Administration, LLC. Upon payment of the principal, accrued interest, and a prepayment fee, all liens were released and the credit agreement was automatically terminated. This action eliminates the company's debt obligations under the Oaktree facility.
- Counterparty
- Oaktree Fund Administration, LLC